Скачайте изображение (превью) выбрав качество

320x180 480x360 640x480 1280x720

Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) sits down with PI, Dr Robert J Mentz (Duke University of Medicine, US) to discuss the findings of the PARAGLIDE-HF trial (NCT03988634).

The PARAGLIDE-HF aimed to evaluate the effects of sacubitril/valsartan compared to valsartan on changes in NT-proBNP, safety, and tolerability in HFpEF patients who have experienced a WHF event (HFpEF decompensation) and have been stabilized and initiated treatment within 30 days post-decompensation.
The results presented at Heart Failure 2023 provide additional evidence supporting the potential treatment benefits of Sac/Val in HF patients with EF less than 40%, particularly those with EF below normal.

Recorded on-site at HFA 2023, Prague.

Visit Radcliffe Cardiology:

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook:
Follow us on Twitter:

Чтобы скачать видео "HFA 23 Late-breaker Discussion: The PARAGLIDE-HF Trial" передвинте ползунок вправо